Cannabis based drug is licensed for spasticity in patients with MSBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c3363 (Published 22 June 2010) Cite this as: BMJ 2010;340:c3363
- Zosia Kmietowicz
The first drug derived from the cannabis plant to be granted a licence by UK authorities has been made available for relief of spasticity in patients with multiple sclerosis.
Sativex oromucosal spray, from Bayer Schering Pharma UK, is indicated as an add-on treatment for patients with moderate to severe spasticity from multiple sclerosis who do not respond adequately to other antispasticity drugs and who show a clinically significant response during an initial trial of the treatment. It contains two cannabinoids in equal quantities: cannabidiol and delta-9-tetrahydrocannabinol.
Spasticity is a common symptom in people with multiple …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial